- Products
- Research Areas
- Epigenetics
- Amino Acids, Drugs and other small molecules
- Apoptosis
- Autophagy
- Cancer
- Cell Biology
- Cell Cycle and Replication
- Cellular Markers
- Cytoskeleton
- DNA Repair
- Epitope Tags
- GPCR
- Hypoxia
- Immunology
- Lipid and Metabolism
- Loading Controls
- MAP Kinase Signaling
- Membrane Trafficking and Chaperones
- Neuroscience
- Nuclear Receptors, Coactivators and Corepressors
- Phospho-Specific
- Protein Kinase
- Protein Phosphatase
- Protein Turnover
- Signal Transduction
- Stem Cell Markers
- Transcription Factors and Regulators
- Translation Control
- Tyrosine Kinases
- Wnt Signaling Pathway
- modENCODE Antibodies
- Support
- Distributors
- About
Support: 303-730-1950
Worldwide (Choose your country.)
![Western Blot: PARP-1 (Cleaved p85) Antibody (Y34) [NB110-57321] - Western blot analysis on (1) Jurkat and (2) Jurkat + Camptothecin using anti-PARP-1 (catalog #110-57321), 1:1,000 dilution.](http://images.novusbio.com/images/p_57321_1.jpg "Western Blot: PARP-1 (Cleaved p85) Antibody (Y34) [NB110-57321] - Western blot analysis on (1) Jurkat and (2) Jurkat + Camptothecin using anti-PARP-1 (catalog #110-57321), 1:1,000 dilution.")
![Flow Cytometry: PARP-1 (Cleaved p85) Antibody (Y34) [NB110-57321] - Analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP-1. Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized, and then stained with anti-cleaved PARP-1. The results indicate that 43% of cells were positive for cleaved PARP (B, M2) after treatment, compared to 9% positive without treatment (A, M2).](http://images.novusbio.com/images/110-57321_2.jpg "Flow Cytometry: PARP-1 (Cleaved p85) Antibody (Y34) [NB110-57321] - Analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP-1. Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized, and then stained with anti-cleaved PARP-1. The results indicate that 43% of cells were positive for cleaved PARP (B, M2) after treatment, compared to 9% positive without treatment (A, M2).")
